BWA
FULC icon

Basecamp Wealth Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Basecamp Wealth Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267 Sell
73
-152
-68% -$925 ﹤0.01% 1714
2026
Q1 		$1.73K Buy
+225
New +$2.09K ﹤0.01% 1438

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Basecamp Wealth Advisors's FULC Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Fulcrum Therapeutics (FULC) stake by 68% in Q2 2026, selling an estimated $925 and leaving 73 shares worth $267. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

Basecamp Wealth Advisors first reported a position in FULC in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.73K in Q1 2026. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Basecamp Wealth Advisors held 73 shares of Fulcrum Therapeutics worth $267 as of Q2 2026.
  • Basecamp Wealth Advisors sold 152 Fulcrum Therapeutics shares in Q2 2026, an estimated $925.
  • Fulcrum Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1714 holding.
  • Basecamp Wealth Advisors first reported a position in Fulcrum Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Basecamp Wealth Advisors's Fulcrum Therapeutics position peaked at $1.73K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.